Cantor Fitzgerald L. P. Acquires Shares of 375,000 Alto Neuroscience, Inc. (NYSE:ANRO)

Cantor Fitzgerald L. P. purchased a new position in Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 375,000 shares of the company's stock, valued at approximately $1,575,000. Cantor Fitzgerald L. P. owned approximately 1.39% of Alto Neuroscience as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in shares of Alto Neuroscience by 40.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock valued at $46,000 after buying an additional 3,139 shares in the last quarter. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Alto Neuroscience in the fourth quarter valued at about $74,000. Jane Street Group LLC lifted its holdings in shares of Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after acquiring an additional 7,783 shares during the period. Rhumbline Advisers grew its position in Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock valued at $108,000 after acquiring an additional 5,008 shares during the period. Finally, Barclays PLC raised its stake in shares of Alto Neuroscience by 34.5% in the fourth quarter. Barclays PLC now owns 39,807 shares of the company's stock valued at $168,000 after acquiring an additional 10,208 shares during the last quarter.

Alto Neuroscience Trading Down 0.9 %

ANRO traded down $0.02 on Wednesday, hitting $2.17. 502,317 shares of the company were exchanged, compared to its average volume of 381,260. Alto Neuroscience, Inc. has a 12 month low of $1.60 and a 12 month high of $17.55. The stock has a market capitalization of $58.75 million, a PE ratio of -0.85 and a beta of 1.87. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The firm has a fifty day simple moving average of $2.52 and a two-hundred day simple moving average of $3.66.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.09. Sell-side analysts expect that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ANRO shares. HC Wainwright assumed coverage on Alto Neuroscience in a research report on Monday, April 7th. They issued a "buy" rating and a $10.00 price target on the stock. William Blair reissued an "outperform" rating on shares of Alto Neuroscience in a research report on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.